Colorectal News and Research

RSS

Scientists find way to prevent early stage pancreatic cancer in research models

Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models - a result that has far-reaching implications in chemoprevention for high-risk patients.

12 Jan 2011

Race, ethnicity and geography influence colon cancer screening

New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.

11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Colorectal cancer screening disparities in certain regions

Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.

10 Jan 2011

Single cellular crisis shatters chromosomes in cancer causation

Remarkable new research overthrows the conventional view that cancer always develops in a steady, stepwise progression. It shows that in some cancers, the genome can be shattered into hundreds of fragments in a single cellular catastrophe, wreaking mutation on a massive scale.

7 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.

5 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Cyfluent Chart, Version 2.0 receives Complete EHR certification

Cyfluent, Inc. announced today that Cyfluent Chart, Version 2.0, is 2011/2012 compliant and was certified as a Complete EHR on Friday, November 12, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the certification criteria adopted by the Secretary of Health and Human Services. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

3 Jan 2011

Cancer survival rates improving

Survival rates for cancers of the bowel, breast, lung and ovary that were diagnosed between 1995 and 2007 were compared between Australia, Canada, Denmark, Norway, Sweden and the UK. Overall, survival rates improved in all six countries. However, survival was found to be “persistently lower” in Denmark, England, Northern Ireland and Wales. This was particularly the case after the first year of diagnosis and for patients aged 65 and over. In UK cancer survival rates have improved significantly. Breast cancer survival at five years, for example, increased from 74.8% in 1995-9, to 81.6% in 2005-7. Despite this, the UK still has the lowest breast cancer survival rate at five years.

27 Dec 2010

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

The cell signaling pathway known as Wnt, commonly activated in cancers, causes internal membranes within a healthy cell to imprison an enzyme that is vital in degrading proteins, preventing the enzyme from doing its job and affecting the stability of many proteins within the cell, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

24 Dec 2010

Researchers discover protein that suppresses melanoma progression

In a breakthrough that could lead to new treatments for patients with malignant melanoma, researchers from Mount Sinai School of Medicine have discovered that a particular protein suppresses the progression of melanoma through regulation of an oncogene, or gene responsible for cancer growth. The study is published in the December 23 issue of Nature.

23 Dec 2010

NCI grants U-M Cancer Center $10.7M for study of colorectal and pancreatic cancer

The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.

23 Dec 2010

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family, "RS7 antibodies," were issued as Patent No. 1,002,443 in Korea.

23 Dec 2010

People with high RBC folate levels more likely to have two tumor-suppressing genes

People with higher levels of folate in their red blood cells were more likely to have two tumor-suppressing genes shut down by methylation, a chemical off switch for genes, researchers report in the December issue of Cancer Prevention Research.

22 Dec 2010

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.

22 Dec 2010

Canadians with lung, breast, colorectal or ovarian cancer have higher survival rate

Canadians with lung, breast, colorectal or ovarian cancer have a higher rate of survival than people diagnosed with these cancers in the United Kingdom, Denmark or Norway, a new international study has found.

22 Dec 2010